TLDR
- Pharmaceutical giant Eli Lilly revealed intentions to purchase three vaccine development companies — Curevo, LimmaTech Biologics, and the Vaccine Company — for approximately $3.8 billion combined.
- The acquisition of Curevo carries a price tag of up to $1.5 billion, with the company currently developing a shingles vaccine targeting adult populations.
- LimmaTech Biologics, which concentrates on vaccines addressing bacterial infections including sexually transmitted diseases, commands a valuation reaching $780 million.
- The Vaccine Company, developing a vaccine for Epstein-Barr virus, has been valued at up to $1.55 billion.
- Shares of LLY climbed approximately 1.3%–1.6% during premarket hours following the announcement.
The pharmaceutical powerhouse Eli Lilly is committing close to $4 billion to establish a foothold in infectious disease prevention. On Tuesday, the company revealed agreements to purchase three biotechnology companies: Curevo, LimmaTech Biologics, and the Vaccine Company.
Shares of LLY experienced gains between 1.3% and 1.6% in premarket activity following the announcement.
The trio of acquisitions features upfront cash payments supplemented by performance-based milestone payments contingent upon clinical development and commercial achievements. The aggregate value approaches $3.83 billion.
This initiative represents a notable strategic pivot for an organization primarily recognized for its highly successful GLP-1 medications. Daniel Skovronsky, Lilly’s chief scientific and product officer, articulated the rationale clearly: “These acquisitions reflect a deliberate strategy to prevent disease at its source rather than treat its consequences.”
Curevo represents the most substantial transaction, valued at up to $1.5 billion. This biotechnology firm has engineered a shingles vaccine incorporating a synthetic adjuvant — formulated to enhance immune system activation while minimizing adverse effects relative to currently available alternatives.
The Vaccine Company follows closely with a valuation reaching $1.55 billion. The company is pioneering In Vivo Nanoparticle technology aimed at combating viral infections, with primary emphasis on Epstein-Barr virus — a widespread pathogen for which no authorized vaccine exists.
LimmaTech completes the acquisition portfolio at up to $780 million. The company’s development pipeline addresses bacterial infections, particularly Neisseria gonorrhoeae and chlamydia trachomatis — organisms exhibiting escalating antibiotic resistance that presents mounting healthcare challenges.
Funded by GLP-1 Success
Lilly’s acquisition campaign draws funding from the extraordinary commercial performance of its diabetes and obesity medications. During the first quarter, Zepbound generated $4.16 billion in U.S. revenue, while Mounjaro contributed $4.2 billion.
This financial strength has enabled Lilly to diversify significantly beyond its weight management product portfolio. The three vaccine acquisitions represent a continuation of Lilly’s strategy to allocate capital toward emerging therapeutic categories while expanding its development pipeline.
The pharmaceutical company currently commands a 60.1% portion of the U.S. obesity medication market, while competitor Novo Nordisk holds 39.4%. Additionally, Lilly introduced Foundayo, its recently authorized GLP-1 obesity tablet formulation, during the second quarter.
Three Vaccines, Three Gaps in the Market
Each acquisition addresses a specific medical need where approved vaccines remain unavailable or existing solutions offer opportunities for advancement.
Approximately one in three Americans will develop shingles during their lifetime. The Epstein-Barr virus has infected around 90% of the worldwide adult population and demonstrates associations with specific malignancies and multiple sclerosis. Bacterial sexually transmitted infections such as gonorrhea increasingly demonstrate resistance to available antibiotic therapies.
Lilly has not publicly revealed the precise upfront payment figures for any acquisition, disclosing only the maximum potential transaction values when including performance milestones.
The Wall Street Journal initially broke the story Tuesday morning ahead of Lilly’s formal confirmation.
